Developing technologies to defeat age-related diseases by keeping people biologically younger is the goal of the rejuvenation biotechnology field. LRI created the Longevity Investor Network (LIN) to connect promising longevity tech companies with investors to get this technology to the clinic.
Looking back at a successful 2024 for the LIN
The Longevity Investor Network (LIN) has experienced significant growth in the last year. We wanted to showcase some of our successes with you in this annual LIN update.
Membership growth & network expansion
In 2024, the Longevity Investor Network experienced significant growth, nearly doubling our investor membership from 205 to 411 members. This expansion has strengthened our ability to connect investors with cutting-edge longevity biotechnology startups, furthering our mission to accelerate innovation in the field.
Investment activity & capital deployment
Our network actively invested in six promising longevity biotech companies, deploying over $650,000 USD in 2024. These investments reflect our commitment to backing innovative solutions that address aging-related diseases and extend human healthspan. The companies we supported in 2024 include:
XM Therapeutics
: ECM drives tissue regeneration and wound healing in all human organs. In acute or chronic organ injuries, especially in the aging population, abnormal ECM healing leads to fibrosis, inflammation & ischemia. XM Therapeutics’ platform technology provides a micro-molded non-adhesive substrate to culture cells in 3D, which allows human ECM particles produced in vitro to repair the abnormal ECM. It has shown that ECM induces recovery of ischemic myocardium by upregulating the protein networks involved in cellular contractility and metabolism.
BioIO: BIOIO is a drug mechanism of action platform company challenging the traditional way of drug discovery by focusing on chemical classes with a disputed MoA currently in use for diseases of aging. Its lead candidate, BIOIO-1001, targets a unique NAD+-dependent pathway, modulating sirtuin 3. This mechanism induces fatty acid oxidation without relying on peroxisome proliferator-activated receptors (PPARs). This makes BIOIO-1001 different from existing metabolic drugs such as fibrates, glitazars, and thiazolidinediones. The compound’s mode of action restores cellular energy balance and improves metabolic function, resulting in significant insulin sensitization. Its drug has great potential to treat type 2 diabeties by addressing insulin resistance at its root.
Oviva Therapeutics: Oviva is focused on enhancing healthspan for women through the creation of innovative therapies that improve ovarian function and longevity. The decline in ovarian function due to aging can result in various health issues for women. As women age, the ovaries produce fewer hormones, particularly estrogen and progesterone. This hormonal shift can lead to a variety of health issues, both physical and emotional.
One of the most commonly recognized consequences is the onset of menopausal symptoms, which can include hot flashes, night sweats, mood swings, and irregular periods. These symptoms can vary in intensity and duration, impacting daily life and overall quality of life. The decline in estrogen levels also has significant implications for bone health. By promoting ovarian health, Oviva seeks to mitigate the adverse effects of menopause, ultimately prolonging women’s healthspan.
BE Therapeutics: BE Therapeutics is focused on creating neocortical tissue to combat brain aging. Its goal is to use technology that can produce functional brain tissue to replace areas of the brain which have been damaged by aging. It has established a technological platform that addresses various challenges, allowing for the engineering of “ready-to-use” cortical replacement tissue aimed at reversing neurodegeneration, starting with stroke as an initial proof-of-concept. The company has secured $3.6 million in seed round funding.
LEAH Labs: LEAH Labs is building a full stack engine for CAR-T cell therapy discovery and commercialization. It is the first in the world to visualize CAR-T cells in a living patient (dog or human) with cancer. Its CAR-T cells have already induced remission in pet dogs with lymphoma. CAR-T cells will bring a revolution to companion animal oncology, as there are 6,000,000 cases of cancer in “human’s best friend” every year. Market approval for lymphoma CAR-T is attainable in under 3 years for under $10M. The company’s bigger vision is to help pets, learn, and apply the technology to people. Its ‘Bits to Therapies’ pipeline identifies novel CAR-T assets faster than biology and uses dogs as a spontaneous disease model to increase the CAR-T cell therapy hit rate.
Vivian Therapeutics: Vivian Therapeutics is a biotechnology company focused on developing innovative therapies for age-related diseases and conditions. It aims to leverage advancements in science and technology to enhance longevity and improve quality of life. One particular focus for the company is cancer, and it uses an approach called the Personal Discovery Process (PDP).
PDP gives people research-based treatment on a large scale, acting like a big clinical trial for one patient. It creates a genetic model of each patient’s unique tumor using 500,000 fruit fly “avatars.” Using robotics, this approach can test up to 2,000 FDA/NICE approved drugs, including non-cancer drugs, in order to find drug combinations that work well for the patient’s avatar group. The Icahn School of Medicine at Mount Sinai developed the PDP method over many years of clinical research and found that real patient tumors can resist treatments that only use one drug. This resistance is caused by changes in several genes, some of which were not previously connected to cancer.Investor engagement & educational initiatives
To foster deeper engagement and informed investing in longevity biotech, we have hosted 25 investor pitch sessions featuring 70+ longevity companies presenting their innovative solutions to our network. These sessions have provided valuable deal flow opportunities and insights into the latest advancements in the field.
Additionally, we conducted five Investor Education Seminars in collaboration with leading organizations and experts, covering critical industry topics.
A growing portfolio of rejuvenation biotech companies
Since 2020, the Longevity Investor Network has invested in 19 companies with over $5,525,000 in promising longevity startups worldwide. Our portfolio companies include:
We are building a pipeline to the clinic
It certainly has been an exciting year for the LIN, and we look forward to continued growth in 2025. LIN project lead Javier Noris had this to say about what the network has achieved so far:
We are living through a remarkable turning point in biomedical history. The longevity biotechnology industry—once considered speculative—is now entering a phase of real-world traction. Investment is accelerating, driven by a new class of sophisticated funds and visionary investors who recognize both the economic potential and humanitarian promise of targeting the root causes of aging.
We’re seeing a wave of therapies in clinical trials, from senolytics to cellular reprogramming, inch closer to public availability. The pipeline is no longer theoretical—it’s operational. What was once science fiction is quickly becoming science fact, and the commercialization landscape is opening doors not just for patient impact, but for sustainable, scalable business models. It’s an incredibly exciting time to be part of this movement.
As the leader of the Longevity Investors Network, I’m thrilled to be doing my part to support and accelerate this progress. If you’re passionate about investing in early-stage startups shaping the future of healthspan and lifespan, I warmly invite you to reach out and join our growing investment community.
Thanks to the work of the LIN, we are moving closer to the day when rejuvenation therapies could be available to the healthcare system.
The Longevity Investor Network is an excellent place to connect with upcoming rejuvenation biotech companies and explore this exciting field. If you are an investor and potentially interested in joining the LIN, please complete the contact form below, and we will be in touch.
